Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

AXGN vs KIDS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AXGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

AXGN Overall Winner 6-Pillar Tally: AXGN 5 – 1 KIDS Matrix Metrics: AXGN 7 – 3 KIDS

As of Nov 19, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXGN carries a Unified Composite Score of 35.3/100 (SELL) at $56.35 (79.7x Forward P/E, -5.2% operating margin), whereas KIDS carries 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin).

  • Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. AXGN 35.3/100 SELL), AXGN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. -8.2% operating margin) and revenue trajectory (+26.2% vs. +18.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXGN vs KIDS
AXGN NASDAQ Head-to-Head Winner
Axogen, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$56.35
-1.05% 1D
Market Cap $3.4B
TTM Revenue $267M
Forward P/E 79.7x
Beta / 30D Vol 1.28β · 121% Vol
Unified Composite Score
35.3 / 100 SELL
Tech 50.0 Fund 28.0 Flow 62.0 Mom 31.6
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 68
RSI-14: 68.4 · SMA20: $50.34 · SMA50: $44.07
KIDS NASDAQ
OrthoPediatrics Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$32.51
+2.72% 1D
Market Cap $850.2M
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 0.81β · 108% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 28.0 Fund 40.0 Flow 50.0 Mom 46.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.1% over 20 days), RSI 64
RSI-14: 64.2 · SMA20: $30.90 · SMA50: $25.86

6-Pillar Scorecard Institutional Category Breakdown (AXGN 5 – 1 KIDS)

Columns: Metric · AXGN · KIDS
1. Valuation Multiples AXGN
Forward P/E 79.7x N/M
Trailing P/E 125.0x N/M
PEG Ratio N/M N/M
EV / Revenue 11.6x 3.2x
2. Growth & Scale AXGN
Revenue Growth (YoY) +26.2% +18.6%
Earnings Growth (YoY) +300.0% +0.0%
TTM Revenue (USD) $267M $264M
Market Cap $3.4B $850.2M
3. Profitability & Quality AXGN
Gross Margin 74.2% 73.8%
Operating Margin -5.2% -8.2%
Net Profit Margin -12.0% -12.8%
Return on Equity (ROE) -10.3% -9.8%
4. Balance Sheet & Cash Flow AXGN
Cash Generation (TTM) $20M $1.1M EBITDA
Cash Flow Margin 7.5% 0.4% EBITDA Mgn
Net Cash / Leverage $309M Net Cash $12.99 Book/Sh · -9.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AXGN
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 67.0% (15th %ile) 145.1% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat KIDS
OpEx & R&D Intensity 79.4% of Rev ($212M) 82.0% of Rev ($217M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXGN (7) vs KIDS (3)
Institutional Metric AXGN KIDS Criterion Row Edge
Market Capitalization
Scale
$3.4B $850.2M Larger Scale AXGN
Trailing P/E Ratio
Valuation
125.0x N/M Lower Multiple AXGN
Forward P/E Ratio
Valuation
79.7x N/M Lower Multiple AXGN
Revenue Growth (YoY)
Growth
+26.2% +18.6% Higher Growth AXGN
Operating Margin (TTM)
Profitability
-5.2% -8.2% Higher Margin AXGN
Net Profit Margin
Profitability
-12.0% -12.8% Higher Margin AXGN
Return on Equity (ROE)
Capital Efficiency
-10.3% -9.8% Higher ROE KIDS
52-Week Range Position
Momentum
91% ($23–$60) 90% ($14–$35) Stronger Trend AXGN
Beta / 30D Volatility
Risk Regime
1.28β · 121% Vol 0.81β · 108% Vol Lower Realized Risk KIDS
Unified Institutional Score
Composite Signal
35.3 / 100 (SELL) 45.1 / 100 (HOLD) Higher Composite KIDS
Trailing 12M Revenue (USD)
Operating Scale
$267M $264M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 73.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 11.6x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($309M Net Cash) $1.1M EBITDA ($12.99 Book/Sh · -9.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AXGN +18.1 pp
AXGN: +54.47% · KIDS: +36.37%
3M Horizon KIDS +14.93 pp
AXGN: +11.81% · KIDS: +26.74%
6M Horizon KIDS +39.99 pp
AXGN: +36.41% · KIDS: +76.4%
1Y Horizon AXGN +35.85 pp
AXGN: +134.69% · KIDS: +98.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXGN vs KIDS. Trailing 12-month operating profitability (AXGN -5.2% vs KIDS -8.2%) and valuation multiples (AXGN 79.7x vs KIDS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AXGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$267M
Gross Margin74.2%
Op. Margin-5.2%
ROE / Fwd P/E-10.3% · 79.7x
KIDS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$264M
Gross Margin73.8%
Op. Margin-8.2%
ROE / Fwd P/E-9.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXGN SURGE
6d in phase · OBV NEUTRAL
Current IV 67.0%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AXGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KIDS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 145.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KIDS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXGN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.4B market capitalization and -5.2% operating margin.
OpEx & R&D Reinvestment 79.4% of Rev ($212M)
90D Engineering Disclosures 0 Published
KIDS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 82.0% of Rev ($217M)
90D Engineering Disclosures 0 Published

Investor FAQ AXGN vs KIDS Key Questions & Quantitative Answers

As of Nov 19, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXGN carries a Unified Composite Score of 35.3/100 (SELL) at $56.35 (79.7x Forward P/E, -5.2% operating margin), whereas KIDS carries 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin). Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. AXGN 35.3/100 SELL), AXGN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. -8.2% operating margin) and revenue trajectory (+26.2% vs. +18.6% YoY).

AXGN leads the Growth & Scale pillar: AXGN posts +26.2% YoY revenue growth and +300.0% YoY earnings growth on $267M TTM revenue (74.2% gross margin, -5.2% operating margin), compared with KIDS at +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin). On trailing 12-month operating scale, AXGN generates $267M in USD-normalized revenue versus $264M for KIDS. In operating R&D and SG&A reinvestment, AXGN deploys 79.4% of Rev ($212M) (0 90-day corporate R&D disclosures) versus 82.0% of Rev ($217M) (0 disclosures) for KIDS.

AXGN screens cheaper on headline valuation multiples. AXGN trades at 79.7x Forward P/E, 125.0x Trailing P/E, N/M PEG, and 11.6x EV/Revenue (7.5% FCF margin), whereas KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXGN (-10.3% ROE) versus KIDS (-9.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AXGN carries 67.0% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.28β · 121% Vol realized risk). By comparison, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.